Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MLNR | O43193 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1788258 | 1.00 | HRH3 (0.47) | HRH3KDM2BCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL1792064 | 1.00 | HRH3 (0.47) | HRH3KDM2BCYP2D6CYP3A4CYP2C9 | |
| SCHEMBL1789971 | 0.84 | HRH3 (0.60) | HRH3KDM2BCYP2D6 | |
| SCHEMBL7949359 | 0.84 | HRH3 (0.50) | HRH3KDM2BCYP2D6MLNRHRH1 | |
| SCHEMBL1790048 | 0.84 | HRH3 (0.51) | HRH3KDM2BCYP2D6MLNR | |
| SCHEMBL1791794 | 0.83 | HRH3 (0.58) | HRH3KDM2BCYP2D6 | |
| SCHEMBL1792067 | 0.82 | HRH3 (0.41) | HRH3CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL1788260 | 0.82 | HRH3 (0.41) | HRH3CYP3A4CYP2C9PKMCYP2C19 | |
| SCHEMBL1790033 | 0.82 | HRH3 (0.49) | HRH3KDM2BCYP2D6MLNRHRH1 | |
| SCHEMBL1786946 | 0.81 | HRH3 (0.47) | HRH3KDM2BCYP2D6MLNRHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885KDM2B 1549/4885CYP2D6 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.